Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
CosentyxⓇ maintains strong market position; progressing LCM
Sales evolution
USD m, % cc
Ex-US
Cosentyx E
AZ
K
K
L
US
FY 4.0bn +13%
FY 4.7bn +17%
1,247 1,243
■
Maintaining strong growth and market position
■ Demand driven across indications in US, Europe, China
Expanding clinical differentiation
Hidradenitis suppurativa Ph3 positive
1,175
1,109
1,012
1,053
◉
Approved for JPSA and ERA in the US
930
944
494
473
460
■
423
372
408
354
330
576
614
640
686
715
753
770
645
Approval for PSO flexible dosing in EU
■ GCA Ph2b positive; Ph3 ongoing
☐
Anticipate 10+ indications overall
Expect double-digit growth in 2022
Expect historical Q1 sales pattern
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
2020
2021
SpA Spondyloarthritis JPSA - Juvenile psoriatic arthritis ERA - Enthesitis related arthritis PSO-Psoriasis GCA Giant cell arteritis LN- Lupus nephritis
LP-Lichen planus
26 Investor Relations | Q4 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation